Navigation Links
Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway

investigation, the existence of this spliced variant in human may explain the evolution biology of SPARC and enhance the understanding of SPARC roles in carcinogenesis (Abstract #2778; Identification of a Splice Variant of Human SPARC mRNA with a Q3 Deletion).

The results of these pre-clinical studies support previous findings presented at the 2006 AACR conference, which demonstrated an increase in tumor response with nab-paclitaxel in SPARC-positive, head-and-neck cancer patients (83 percent) versus SPARC-negative, head-and-neck cancer patients (25 percent).

Abraxis continues to explore the role of nab-technology for targeting SPARC and other biological pathways, as well as for the development of new therapeutic candidates such as nab-docetaxel (ABI-008), the mTOR inhibitor nab-rapamycin (ABI-009), and the HSP90 inhibitor nab-17-AAG (ABI 010), among others.

About nab(TM) Technology Platform

Developed by Abraxis BioScience, nanoparticle albumin-bound (nab(TM)) tumor-targeting technology harnesses the unique natural properties of the human protein albumin, to transport and deliver therapeutic agents to the site of disease. The binding of albumin to the anticancer agent creates nanometer-sized particles, which are approximately 1/100th the size of a single red blood cell. These nab particles are readily incorporated into the body's own transport processes and are able to exploit the tumors' attraction to albumin, enabling the delivery of higher concentrations of the active drug to the target site. This may lead to an increase in the drug's antitumor effect and the potential for an effective response. In addition, nab technology offers the ability to improve a drug's solubility by avoiding the need for toxic chemicals, such as solvents, in the administration process, thus potentially improving safety through the elimination of solvent-related side effects.

Abraxis BioScience received approval from the U.S. Food and Drug Administration
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... industry is expecting a busy summer this year, and ... Day weekend, more hotels and resorts are raising their ... according George Clarke, CEO of UMF Corporation, a developer ... hotels and resorts adopting environmental hygiene practices developed for ...
... SAN FRANCISCO, May 22, 2012  Boehringer Ingelheim announced ... the investigational compound tiotropium delivered once-daily via the ... moderate persistent asthma. The data were presented at ... Society (ATS 2012). Boehringer Ingelheim announced that a ...
Cached Medicine Technology:With Busy Summer Forecast Ahead, More Hotels Are Raising Hygiene Standards, Says UMF Corporation 2Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 2Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 3Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 4
(Date:4/24/2014)... 4/24/14) Dartmouth has been awarded one of 30 ... as a Lead Academic Participating Site in its new ... recipients are a select groups of investigators charged with ... cooperative groups., The NCTN grant system reflects recommendations from ... streamlines operations to achieve four goals:, Faster ...
(Date:4/23/2014)... (MGH) investigators may lead to greater availability and acceptability ... use of fecal material from healthy donors to ... ( C. difficile ) bacteria. In their ... Infectious Diseases , the researchers report that use of ... was as successful in curing recurrent C. difficile ...
(Date:4/23/2014)... M.D., scientific director at the National Institute of Arthritis ... the 2014 recipient of the Ross Prize in Molecular ... Molecular Medicine . The award will be given ... Sciences in Manhattan, followed by scientific presentations by Dr. ... the National Institutes of Health. , The award, which ...
(Date:4/23/2014)... enzyme pathway that helps prevent new cells from receiving ... has been directly linked to cancer and other diseases. ... near the end of cell division, the enzyme Cdc14 ... DNA are fully repaired before the parent cell distributes ... helps safeguard against some of the most devastating genome ...
(Date:4/23/2014)... In science, "simple and accessible detection methods that ... the resolution of a single cell inside that ... chemical engineer Chang Lu. , In the Royal ... Lu has announced that he and his coworkers ... subcellular location of a protein ( Chem. Sci. ...
Breaking Medicine News(10 mins):Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... Revenue Up 16% ... Cellulite Product Launch Targeted for Late Q1 ... Company Updates Guidance for Full Year 2007, HAYWARD, Calif., Nov. 6 ... the aesthetic,industry, today reported its financial results for the third quarter ended,September 30, ...
... Organizations Rapidly Identify High-Risk Cases, Provide ... BIRMINGHAM, Ala., Nov. 6 The ... DST Health Solutions announced that 16,organizations have ... helps organizations rapidly identify at-risk patients for,care ...
... - Continued progress in both core business segments supports ... Corporation,(Nasdaq: VRNM ), a leading developer of technologies ... of high-performance specialty,enzymes, today reported financial results for the ... "We are very pleased with the progress the Company ...
... Mass., Nov. 6 Biopure Corporation,(Nasdaq: BPUR ... public,offering of stock and warrants that raised net ... exercise of the warrants. Biopure,sold 19,377,500 new shares ... an,additional 19,377,500 shares, including 2,527,500 shares and 2,527,500,warrants ...
... group says , TUESDAY, Nov. 6 (HealthDay News) -- Standard ... been proposed by a team of Johns Hopkins experts, who ... comparisons and help improve patient safety. , "Hospitals are ... this is long overdue, the data is only helpful if ...
... for patients with sudden, life-threatening attacks, trial shows , , ... kind of medication has failed as treatment for the ... trial finds. , The drug, tezosentan, did not improve ... or cut their risk of death after acute ...
Cached Medicine News:Health News:Thermage Announces Third Quarter Financial Results 2Health News:Thermage Announces Third Quarter Financial Results 3Health News:Thermage Announces Third Quarter Financial Results 4Health News:Thermage Announces Third Quarter Financial Results 5Health News:Thermage Announces Third Quarter Financial Results 6Health News:Thermage Announces Third Quarter Financial Results 7Health News:Thermage Announces Third Quarter Financial Results 8Health News:Thermage Announces Third Quarter Financial Results 9Health News:Sixteen Organizations Implement ACG Rx-PM Predictive Modeling from Johns Hopkins University, DST Health Solutions 2Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 2Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 3Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 4Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 5Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 6Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 7Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 8Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 9Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 10Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 11Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 12Health News:Experimental Drug Fails Against Heart Failure 2Health News:Experimental Drug Fails Against Heart Failure 3
... latest in the Magnes line of biomagnetometer systems, ... full cortical coverage, provides the highest detector density ... of a wide range of neuronal activity. The ... detector configurations and can be equipped with radial ...
... for basic and advanced NCS, ... large 12.1" XGA (1024 x ... the latest in technology allow ... advanced NCS capabilities, advanced EMG ...
... is a non-invasive and painless method of ... Cadwell Laboratories manufactures two magnetic stimulation devices, ... Stimulator (HSMS). The Hight Speed MES-10 magnetic ... to 25 Hz at full power. Several ...
... are the latest innovation ... portable battery-powered EEG headboxes. ... new mechanical design, and ... standard MOBEE24plus and MOBEE32 ...
Medicine Products: